Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Synektik Signs Max 11 Mln Zloty In-Consortium Deal For AI Breast Cancer Detection Models
3+ hour, 34+ min ago (29+ words) TradingView Synektik Signs Max 11 Mln Zloty In-Consortium Deal For AI Breast Cancer Detection Models...
Biovica receives new extensive Pharma Services work order from existing customer
2+ day, 2+ hour ago (184+ words) Biovica, a company specializing in blood-based cancer monitoring and oncology drug development services, today announced that it has received a new Pharma Services work order from an existing TIER-2 pharmaceutical customer. The work order covers DiviTum® TKa testing for an…...
Roche Canada & PCPA Complete Negotiations For Perjeta For Neoadjuvant Treatment Of Early Stage Breast Cancer — TradingView News
2+ day, 18+ hour ago (31+ words) Roche Canada & PCPA Complete Negotiations For Perjeta For Neoadjuvant Treatment Of Early Stage Breast Cancer TradingView Roche Canada & PCPA Complete Negotiations For Perjeta For Neoadjuvant Treatment Of Early Stage Breast Cancer...
Prelude Therapeutics reports Q2 2026 results: $5.7M revenue, $13.9M net loss, $155.2M cash — TradingView News
1+ week, 2+ day ago (259+ words) Prelude Therapeutics reports Q2 2026 results: $5.7M revenue, $13.9M net loss, $155.2M cash TradingView Prelude Therapeutics reports Q2 2026 results: $5.7M revenue, $13.9M net loss, $155.2M cash Prelude Therapeutics reported second-quarter 2026 results with revenue of $5.7 million and a net loss of $13.9 million ($0.14 per share). The company ended June 30, 2026 with $155.2 million…...
Here's Why You Should Add ANIX Stock to Your Portfolio Now
1+ mon, 3+ week ago (374+ words) A key strength of Anixa’s strategy is its partnerships with leading cancer research institutions, leveraging expertise from the Moffitt Cancer Center for its ovarian cancer CAR-T program and the Cleveland Clinic for its cancer vaccine platform. Over the past three…...
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
2+ mon, 1+ week ago (801+ words) Shares of Puma Biotechnology PBYI have witnessed a sharp increase in the past three months, driven by investor optimism surrounding the company's strong 2026 revenue outlook. The company's top line is primarily driven by sales of its sole marketed product, Nerlynx…...
Moneycontrol Pro Panorama | Making it rain
2+ mon, 2+ week ago (478+ words) India needs two kinds of rain desperately, the monsoon rains as well as a shower of dollars. Only one of them was in the hands of the Reserve Bank of India and the central bank has made sure it does…...
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
2+ mon, 3+ week ago (31+ words) TradingView Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo More news from Reuters...
EU regulator recommends positive opinion of AstraZeneca’s experimental breast cancer drug
2+ mon, 4+ week ago (29+ words) TradingView EU regulator recommends positive opinion of AstraZeneca’s experimental breast cancer drug More news from Reuters...
Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
3+ mon, 6+ day ago (57+ words) TradingView Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients More news from Reuters...